Updated 06:11 GMT, 17 Nov 2026 SPX 7,416.59 -1.92% NDX 27,197.15 -2.67% VIX 22.91 +18.70% GOLD 3,883.00 +0.78% CL 84.99 -0.85% BTC 64,683.65 -0.95%
NAS100 27,197 −2.67% S&P 7,417 −1.92% GOLD $3,883 +0.78% BTC $64,684 −0.95% VIX 22.91 +18.70% latest tape · as of 06:11 UTC
The Screen · Healthcare · Biotechnology

Candel Therapeutics, Inc.

CADL · Nasdaq · USD · Market cap $694M · 55 employees

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.

Not yet scored
6.20 USD

Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago

Screened 2026-11-13 · the tape above runs as of 06:11 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price6.20 USD at the 13 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.68x the price, above our 2.00x limit.
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenNot yet scored
  • OptionsOpen interest leans heavily to calls (put/call 0.00)
  • Last reviewed13 Nov 2026 (4 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Distribution ?
Screened · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.00, read 2026-11-15
  • Ethical screen not yet scored
Price6.20 USD
Fair valueUnder review
Ethical score90.0/100
Our investment reviews on this name
2026-11-12Read Distribution9.22-32.8% to today ✓Markdown gives way to Distribution after a 20% slide in 6 weeks
2026-10-02Read Markdown11.55-46.3% to today ✓Accumulation gives way to Markdown after a 14% slide in 6 weeks
2026-08-24Read Accumulation13.50-54.1% to today Markup gives way to Accumulation after a 59% rise in 8 weeks
2026-07-02Read Markup8.51-27.1% to today First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Candel Therapeutics, Inc. holds its Distribution at $6.20. Consolidating, no directional conviction, held for 1 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 1 days
Price at the screen$6.20
ValuationN/A trailing · -14.51 forward price to earnings
Values screenNot scored · score 90.0
Beta-0.31
The Workings

Five Screens, Shown in Full

This security has not been fully scored against the values screen yet.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 7.65% Below 33% Interest-bearing debt is just 7.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 18.68% Below 33% Cash held in interest-bearing accounts and securities is 18.7% of assets, under the one-third limit. Pass
Receivables 0.00% Below 49% Money owed to the company is 0.0% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

The Read, in Plain English

Candel Therapeutics, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

2026-10-25

Candel Therapeutics, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

2026-09-24 Clears

Candel Therapeutics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 8%, inside the ~33% line, and almost none of its income is interest, so it passes.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.68x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

How a fair value is estimated: discounted cash flow (DCF).

The Street's Range
15.00Street low 22.50Street average 29.00Street high 6.20Price

Third-party analyst targets: 8 covering, consensus Strong Buy. The average target sits +263% from the screen price.

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-14.5x
EPS, trailing-1.46
EPS, forward-0.63
Profit margin0.0%currently unprofitable
Return on equity-81.8%not currently earning a positive return on equity
FCF yield-5.15%
Debt to equity0.39minimal debt: a conservative balance sheet
Current ratio16.09comfortably covers its short-term bills
Beta-0.31barely tracks the market's swings
Short interest, float0.22%
52-week range4.35 - 14.00
Market cap$694M
Employees55

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

CADL trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-12 Distribution · changed $9.22 -1.4% Entry 18

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-11 Markdown $9.35 -1.5% Entry 17

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-10 Markdown $9.49 +8.5% Entry 16

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-09 Markdown $8.75 +0.0% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-08 Markdown $8.75 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-07 Markdown $8.75 +8.8% Entry 13

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-06 Markdown $8.04 -11.2% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-05 Markdown $9.05 +2.6% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-04 Markdown $8.82 -1.0% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20.

2026-10-28 Markdown $8.91 +0.0% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on CADL

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in CADL's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · CADL
DateInsiderTitleTypeSharesValue
2026-02-23 MANNING PAUL B. Director 550,458 $2,999,996
2025-07-28 NICHOLS WILLIAMS GARRETT Officer 937 $6,540
2025-07-28 NICHOLS WILLIAMS GARRETT Officer 937 $1,209
2025-06-30 NICHOLS WILLIAMS GARRETT Officer 781 $3,936
2025-06-30 NICHOLS WILLIAMS GARRETT Officer 781 $1,007
2025-06-25 PAPA JOSEPH C Director 64,239 $299,996
2025-06-25 MANNING PAUL B. Director 1,070,663 $4,999,996
2025-06-25 NABEL GARY J. Director 5,353 $24,999
2025-06-25 MARTELL CHRISTOPHER Director 111,349 $520,000
2025-06-25 TAK PAUL PETER Chief Executive Officer 42,826 $199,997

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $8.85 -7.7% · $923 -7.7%
2 months $4.83 +69.2% · $1,692 +69.2%
3 months $4.98 +64.1% · $1,641 +64.1%
6 months $6.47 +26.3% · $1,263 +26.3%
1 year $5.85 +39.7% · $1,397 +39.7%
2 years $7.03 +16.2% · $1,162 +16.2%
3 years $1.47 +455.8% · $5,558 +455.8%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever CADL does next, these words stay.

Candel Therapeutics, Inc. · CADL · Distribution · $6.20
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.